Turbulence at the CDC; How Scripps reinvented its financial model; Biopharma’s return to MC4R; and morenews2025-08-30T10:00:18+00:00August 30th, 2025|Endpoints News|
Viking’s obesity readout; George Church lab closer to creating human eggs; Skyhawk gets new pharma partnernews2025-08-23T10:00:09+00:00August 23rd, 2025|Endpoints News|
Bayer bets big on KRAS inhibitor; Treg biotech shuts down; Novartis touts trial wins; and morenews2025-08-16T10:00:43+00:00August 16th, 2025|Endpoints News|
Eli Lilly’s obesity pill data; This week’s Q2 highlights; Biogen’s latest reinvention; and morenews2025-08-09T10:00:37+00:00August 9th, 2025|Endpoints News|
Prasad departs FDA; Merck cuts $3B in costs; Trump renews call for ‘most favored nation’ plan; and morenews2025-08-02T10:00:28+00:00August 2nd, 2025|Endpoints News|
Sarepta fallout continues; MAHA is angry as Loomer points fingers; A CAR-T week in biotech; and morenews2025-07-26T10:00:41+00:00July 26th, 2025|Endpoints News|
Sarepta’s crisis week; Prasad overrides reviewers again; A new study’s clues about Alzheimer’s; and morenews2025-07-19T10:00:57+00:00July 19th, 2025|Endpoints News|
Biopharma’s highest-paid CEOs; John Carroll’s Q2 analysis; Merck to buy Verona Pharma for $10B; and morenews2025-07-12T10:00:24+00:00July 12th, 2025|Endpoints News|
Apple Tree says its biotechs face ‘imminent collapse’; Advocates urge J&J to proceed with eye gene therapy; AbbVie buys in vivo CAR-T maker Capstan; and morenews2025-07-05T10:00:03+00:00July 5th, 2025|Endpoints News|
Sources say FDA commissioner sought rejection of KalVista’s rare disease drug; FDA looks into Sarepta’s Duchenne therapy after deaths; and morenews2025-06-28T10:00:05+00:00June 28th, 2025|Endpoints News|
